A new perspective on metformin therapy in type 1 diabetes

Metformin is quite frequently used off-label in type 1 diabetes to limit insulin dose requirement. Guidelines recommend that it can improve glucose control in those who are overweight and obese but evidence in support of this is limited. Recently-published findings from the REducing with MetfOrmin V...

Descripción completa

Detalles Bibliográficos
Autores principales: Livingstone, Rachel, Boyle, James G., Petrie, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552844/
https://www.ncbi.nlm.nih.gov/pubmed/28770327
http://dx.doi.org/10.1007/s00125-017-4364-6
_version_ 1783256532162445312
author Livingstone, Rachel
Boyle, James G.
Petrie, John R.
author_facet Livingstone, Rachel
Boyle, James G.
Petrie, John R.
author_sort Livingstone, Rachel
collection PubMed
description Metformin is quite frequently used off-label in type 1 diabetes to limit insulin dose requirement. Guidelines recommend that it can improve glucose control in those who are overweight and obese but evidence in support of this is limited. Recently-published findings from the REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL) trial suggest that metformin therapy in type 1 diabetes can reduce atherosclerosis progression, weight and LDL-cholesterol levels. This provides a new perspective on metformin therapy in type 1 diabetes and suggests a potential role for reducing the long-term risk of cardiovascular disease. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00125-017-4364-6) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
format Online
Article
Text
id pubmed-5552844
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-55528442017-08-25 A new perspective on metformin therapy in type 1 diabetes Livingstone, Rachel Boyle, James G. Petrie, John R. Diabetologia Review Metformin is quite frequently used off-label in type 1 diabetes to limit insulin dose requirement. Guidelines recommend that it can improve glucose control in those who are overweight and obese but evidence in support of this is limited. Recently-published findings from the REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL) trial suggest that metformin therapy in type 1 diabetes can reduce atherosclerosis progression, weight and LDL-cholesterol levels. This provides a new perspective on metformin therapy in type 1 diabetes and suggests a potential role for reducing the long-term risk of cardiovascular disease. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00125-017-4364-6) contains peer-reviewed but unedited supplementary material, which is available to authorised users. Springer Berlin Heidelberg 2017-08-02 2017 /pmc/articles/PMC5552844/ /pubmed/28770327 http://dx.doi.org/10.1007/s00125-017-4364-6 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Livingstone, Rachel
Boyle, James G.
Petrie, John R.
A new perspective on metformin therapy in type 1 diabetes
title A new perspective on metformin therapy in type 1 diabetes
title_full A new perspective on metformin therapy in type 1 diabetes
title_fullStr A new perspective on metformin therapy in type 1 diabetes
title_full_unstemmed A new perspective on metformin therapy in type 1 diabetes
title_short A new perspective on metformin therapy in type 1 diabetes
title_sort new perspective on metformin therapy in type 1 diabetes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552844/
https://www.ncbi.nlm.nih.gov/pubmed/28770327
http://dx.doi.org/10.1007/s00125-017-4364-6
work_keys_str_mv AT livingstonerachel anewperspectiveonmetformintherapyintype1diabetes
AT boylejamesg anewperspectiveonmetformintherapyintype1diabetes
AT petriejohnr anewperspectiveonmetformintherapyintype1diabetes
AT anewperspectiveonmetformintherapyintype1diabetes
AT livingstonerachel newperspectiveonmetformintherapyintype1diabetes
AT boylejamesg newperspectiveonmetformintherapyintype1diabetes
AT petriejohnr newperspectiveonmetformintherapyintype1diabetes
AT newperspectiveonmetformintherapyintype1diabetes

Ejemplares similares